Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$9.33 USD
+0.51 (5.78%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $9.34 +0.01 (0.11%) 5:30 PM ET
1-Strong Buy of 5 1
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TBPH 9.33 +0.51(5.78%)
Will TBPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Here's Why You May Invest in Theravance (TBPH) Stock Now
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Other News for TBPH
Mama's Creations, GameStop And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Sidoti Events, LLC's Virtual June Small-Cap Conference
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Theravance Biopharma (TBPH) Receives a Hold from TD Cowen
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Theravance Biopharma (TBPH)